New Appointments Provide Company with Significant Executive Leadership, Global Product Development, Public Health and Retail Pharmacy Market Experience
BETHLEHEM, Pa., November 08, 2021 (GLOBE NEWSWIRE) – OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today hui the appointment of Nancy J. Gagliano, MD and Anne C. Whitaker to the Board of Directors of the Company, effective November 8, 2021. Dr. Gagliano was a practicing physician in internal medicine, has extensive leadership experience in retail pharmacy and was a leader of RADx Tech, a rapid diagnostic acceleration program for the National Institute of Health to bring new diagnostic technologies to market to counter the global COVID-19 pandemic. Dr Gagliano will serve as a Class III director with an initial term expiring at the company’s annual meeting of shareholders in 2024. She will also serve on the nominating and corporate governance committee of the board of directors. . Ms. Whitaker has held a number of managerial and managerial positions in the pharmaceutical industry. She was recognized by Fierce Pharma as one of BioPharma’s 25 Most Influential Women, PharmaVoice as one of the 100 Most Inspirational Health Leaders and Women, Inc. as one of the Corporate Directors most influential. She is currently Chairman of the Board of Aerami Therapeutics. Ms. Whitaker will serve as a Class II Director with an initial term expiring at the Company’s annual meeting of shareholders in 2023. She will also serve on the Audit Committee of the Board of Directors.
âWe are exceptionally privileged to welcome two new Board members of the caliber and experience of Nancy and Anne to our team,â said Stephen S. Tang, Ph.D., President and CEO from OraSure Technologies. “Their knowledge bases in critical areas such as global product development, public health and the retail pharmacy market will be critical as we seek to drive innovation and execute our long-term global growth strategy. “
Dr Gagliano, 62, has more than 35 years of experience as a senior healthcare practitioner and medical practitioner in internal medicine. Dr. Gagliano most recently served as Executive Director of the RADx Tech, Rapid Acceleration of Diagnostics program at the National Institute of Health. In this role, she helped oversee more than $ 1 billion in sponsored programs to bring millions of new COVID-19 tests to market. Prior to working for the National Institute of Health, Dr Gagliano was the Chief Medical Officer of Culbert Healthcare Solutions, providing strategic advice on healthcare consulting services. Prior to joining Culbert Healthcare, Dr Gagliano spent six years at CVS Health, holding leadership roles including as Medical Director of Minute Clinic, and as Senior Vice President overseeing key programs such as the smoking cessation in the company and the development of the company program. telemedicine program. Prior to her leadership roles at CVS Health, Dr. Gagliano was a physician in internal medicine and held numerous leadership positions at the Massachusetts General Hospital and the Massachusetts General Physicians Organization.
Dr Gagliano holds an MD from Harvard Medical School, an MBA from Northeastern University, and a BS from Union College in computer science and biology.
Ms. Whitaker, 54, is a seasoned healthcare executive and director with over 30 years of experience and a proven track record as a leader in building and leading high performance teams. Ms. Whitaker is currently Managing Partner of Anne Whitaker Group, LLC, a board of directors and private equity consultancy, and is the current Chairman of the Board of Aerami Therapeutics, a private life sciences firm. . Prior to assuming the role of President of Aerami, Anne was CEO from October 2018 to November 2020 and a director from July 2018. She is also an independent director on the boards of directors of three public companies, including Faron Pharmaceuticals, a developing pharmaceutical company. business; Caladrius, a developing biotechnology company; and Mallinckrodt, a specialty pharmaceutical company. In addition to her work on the Board of Directors, she is an active sector advisor to private equity and venture capital funds in the United States and Europe. Ms. Whitaker began her healthcare career with The Upjohn Company, which sold pharmaceuticals. She then moved to GlaxoSmithKline PLC where she spent 19 years and rose through the business ranks of a sales representative to become Senior Vice President, Business Unit Head for the Cardiovascular, Metabolic and Urology franchises in 2009. Anne a joined Sanofi SA in 2011 as President of the North American Pharmaceutical Region. Anne was CEO and President of Synta Pharmaceuticals, Inc. in 2014 and 2015. She joined Bausch Health as Executive Vice President and President of the Group of Companies for the Branded Pharmaceuticals segment in mid-2015. From February 2017 to April 2018, she was CEO and President of Novoclem Therapeutics, Inc.
Ms. Whitaker holds a Bachelor of Science in Chemistry from the University of North Alabama.
About OraSure Technologies
OraSure Technologies enables the global community to improve health and wellness by providing access to accurate and essential information. OraSure, with its wholly owned subsidiaries, DNA Genotek, Diversigen and Novosanis, provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular service solutions designed to discover and detect critical medical conditions. OraSure’s product portfolio is sold worldwide to clinical laboratories, hospitals, physician offices, clinics, public and community health organizations, research institutes, government agencies, pharmaceutical companies, commercial entities and directly to consumers. For more information on OraSure Technologies, please visit www.orasure.com.
|Investor contact:||Media contact:|
|Scott gleason||Amy koch|
|Interim CFO & SVP Investor Relations & Communication Corp.||Sr Mgr. Business communication|